Table 3.
Details of AEs, drug substitutions and treatment interruptions among patients with incident AEs up to 24 months of second-line initiation
| Initial second-line ART regimen | Total | ||||
|---|---|---|---|---|---|
| 3TC + ABC + LPVr/ATVr | AZT + 3TC + LPVr/ATVr | AZT + ddI + LPVr | TDF + FTC/3TC + LPVr | ||
| n (col %) | n (col %) | n (col %) | n (col %) | n (col %) | |
| [N = 117] | [N = 1298] | [N = 822] | [N = 1192] | [N = 3429] | |
| First AE in the observation period | |||||
| Anaemia | 80 (68.4) | 1015 (78.2) | 524 (63.6) | 711 (59.7) | 2330 (68.0) |
| Decreased kidney function | 28 (23.9) | 77 (5.9) | 8 (1.0) | 151 (12.7) | 264 (7.7) |
| Dyslipidaemia | 2 (1.7) | 68 (5.2) | 60 (7.3) | 115 (9.7) | 245 (7.1) |
| Gastrointestinal conditions | 2 (1.7) | 52 (4.0) | 83 (10.1) | 82 (6.9) | 219 (6.4) |
| Neuropathy | 2 (1.7) | 28 (2.2) | 44 (5.4) | 52 (4.4) | 126 (3.7) |
| Skin conditions | 3 (2.6) | 29 (2.2) | 49 (6.0) | 40 (3.4) | 121 (3.5) |
| Others | – | 29 (2.2) | 54 (6.6) | 41 (3.4) | 124 (3.6) |
| Frequency of AE episodes in the initial 24 months of second-line ART | |||||
| One | 39 (33.3) | 594 (45.8) | 342 (41.6) | 681 (57.1) | 1656 (48.3) |
| Two | 20 (17.1) | 335 (25.8) | 209 (25.4) | 264 (22.2) | 828 (24.2) |
| Three or more | 58 (49.6) | 369 (28.4) | 271 (33.0) | 247 (20.7) | 945 (27.6) |
| Drug substitutions on second-line ART (24 months) | |||||
| None | 177 (74.4) | 2097 (78.1) | 885 (59.0) | 2608 (79.4) | 5767 (74.8) |
| One | 38 (16.0) | 345 (12.8) | 446 (29.7) | 471 (14.4) | 1300 (16.9) |
| Two | 12 (5.0) | 171 (6.4) | 134 (8.9) | 154 (4.7) | 471 (6.1) |
| Three or more | 11 (4.6) | 70 (2.6) | 36 (2.4) | 50 (1.5) | 167 (2.2) |
| Treatment interruptions on second-line ART (24 months) | |||||
| None | 216 (90.8) | 2491 (92.7) | 1273 (84.8) | 3019 (92.0) | 6999 (90.8) |
| One | 19 (8.0) | 180 (6.7) | 205 (13.7) | 243 (7.4) | 647 (8.4) |
| Two | 2 (0.8) | 13 (0.5) | 22 (1.5) | 17 (0.5) | 54 (0.7) |
| Three or more | 1 (0.4) | 2 (0.1) | 1 (0.1) | 4 (0.1) | 8 (0.1) |
AEs adverse events, ART antiretroviral therapy, 3TC lamivudine, ABC abacavir, LPVr lopinavir/ritonavir, ATVr atazanavir/ritonavir, AZT zidovudine, ddl didanosine, TDF tenofovir, FTC emtricitabine